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Objectives: Side-effects of anti-epileptic drugs (AEDs) may be overlooked in patients
with epilepsy in everyday clinical practice. The aim of this study was to assess the
prevalence and severity of subjective complaints in patients who were considered to
be well-controlled and to assess whether these complaints are related to medication,
personality traits, or other determinants.
Methods: We included patients with epilepsy who were considered to be well-
controlled in a cross-sectional study in seven hospitals in the Netherlands. Their* Corresponding author. Tel.: +31 10 291 1911; fax: +31 10 2911072.
E-mail address: donselaarc@mcrz.nl (C.A. van Donselaar).
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medication had not been changed for sixmonths and an apparent reason to change the
medication was lacking at the time of enrolment. Subjective complaints were
assessed with a 46-item questionnaire. Using multivariable linear regression model-
ing, we assessed whether patient characteristics, epilepsy characteristics, medica-
tion, quality of life (Qolie-10), and personality traits (SCL-90) explained the presence
and severity of complaints.
Results: Of 173 included patients, 67% reported moderate to severe subjective
complaints on the questionnaire. Cognitive complaints were reported most fre-
quently. Multivariate modeling showed that 61% of the variance in reported com-
plaints could be explained by included determinants. The prevalence and severity of
complaints was associated with AED polytherapy and higher scores on psycho neuroti-
cism.
Conclusions: Patients who were considered to be well-controlled proved to report
an unexpectedly high number of subjective complaints. Both medication and
aspects of personality contributed to the level of complaints. Our study illustrates
that subjective side-effects are easily overlooked in everyday clinical practice,
possibly because in practice a generally phrased question is used to detect side-
effects.
# 2006 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.Introduction
The goal of treatment with antiepileptic drugs
(AEDs) is to control epileptic seizures without
causing side-effects.1 However, side-effects or sub-
jective complaints may be overlooked easily. Side-
effects may start insidiously, patients may not
associate their complaints to the medication and
identification of for example cognitive complaints
or mental slowing may be quite difficult.2—4 Disre-
garding side-effects may interfere with the well
being of the patients.2,3,5—7
Two recent studies showed that complaints
attributed to AEDs are frequently overlooked in
clinical practice.2,5 A study by Gilliam et al. showed
unexpected, toxic side-effects in 31% of 200
screened patients from outpatient epilepsy clinics.
They concluded that systematic screening of side-
effects in all patients on AEDs would be useful.5
A cross-sectional study in pharmacies by our group
showed that 60% of patients with epilepsy using
AEDs reported one or more complaints on a ques-
tionnaire.2
Earlier studies did not assess the relation
between reported side-effects and AED use or other
determinants. Furthermore, the occurrence of side-
effects or subjective complaints in patients who
seem well-controlled was never assessed.
The aim of this cross-sectional study was to
assess the prevalence and severity of sub-
jective complaints in patients with epilepsy who
are considered to be well-controlled with AEDs by
their treating physician. In addition, we ass-
essed whether these complaints were related to
AEDs or other determinants, such as personality
traits.Patients and methods
Patients and setting
Seven hospitals in the Netherlands participated in
this cross-sectional study. The medical ethics com-
mittees of each participating hospital approved
the protocol.
Between October 2002 and July 2005 patients
were asked to participate in the study if they were
18 years or older and had well-controlled epilepsy,
defined as no medication change in the past six
months and no obvious clinical reason to change
the medication at the time of inclusion. Patients did
not have to be seizure free to be considered well-
controlled. We excluded patients with a concurrent
disease or disorder that might interfere with the
conduct of the study, such as impaired intellectual
functioning or other reasons leading to inability to
comply with the protocol or complete the necessary
questionnaires.
Data
From every patient, age, sex, length and weight was
documented, as well as type of epilepsy, aetiology,
seizure frequency, time since diagnosis, and time
since the last seizure. We recorded the current use
of AEDs and the number of AEDs used over the years.
Symptom check list
All patients filled out a questionnaire on psycho
neuroticism: the Dutch version of the Symptom
Check List (SCL-90),8,9 to assess the tendency to
complain in general.
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Table 1 Patient characteristics (N = 173)
Age (years) 48 (17)
Sex (% men) 50
Body height (cm) 172 (11)
Body weight (kg) 76 (14)






duration of epilepsy (years)
6 (0—65)
Median (range) number of
seizures during the last month
0 (0—180)
Median (range) time since
last seizure (years)
2 (0—55)
Number of used AEDs
over the years
2.2 (1.4)
Monotherapy AED (%) 85




Values are mean (standard deviation) unless otherwise
indicated.Quality of life
A brief quality of life questionnaire, specific for
epilepsy, was completed (Qolie-10).10
The higher the score on the Qolie-10, the better
the quality of life. The Qolie-10 includes two ques-
tions assessing physical and mental side-effects
(‘‘Are you bothered by physical/mental effects of
anti-epileptic drugs’’). These two questions were
separately analysed.
Subjective complaints
Complaints were assessed using a list of 46 items
with possible AED-related complaints,2,5 the SIDAED
(Appendix A). The included items form 10 cate-
gories: general CNS, behavior (increased irritabil-
ity), depressive symptoms, cognitive function,
motor problems and co-ordination, visual com-
plaints, headache, cosmetic and dermatological
complaints, gastrointestinal complaints, and sexu-
ality and menses (Appendix B). For each item the
patient rates the severity of the complaint on a four-
point Likert scale (no problem, mild, moderate, or
serious problem). In addition, the duration of the
complaints is scored (since a few weeks, since
months or half a year or longer).
Data analysis
A total subjective complaints score was calculated
for each patient from the SIDAED complaints ques-
tionnaire, consisting of the number of mentioned
complaints, weighing a mild score as 1, moderate as
2 and severe as 3 points. Thus, the range of the total
complaints score could vary from 0 to 138.
We used univariable and multivariable linear
regression modeling with the total weighted com-
plaint score (SIDAED) as the outcome (dependent
variable) and patient and epilepsy characteristics,
Qolie-10, and SCL-90 as determinants (independent
variables). In the multivariable analysis, besides
gender, we included determinants that were statis-
tically significantly associated with the outcome in
the univariable analysis (p-value <0.05). Since the
SCL-90, Qolie-10 and SIDAED may be partly over-
lapping measures, we repeated the multivariable
analysis excluding either the Qolie-10 or the SCL-90.
Additionally, we determined the difference
between assessing complaints with a detailed ques-
tionnaire or asking a general phrased question, by
comparing the findings on the 46-item SIDAED with
the two general Qolie-10 questions concerning phy-
sical and mental effects of AEDs. For that purpose,
the SIDAEDwas also divided into physical andmental
complaints. The categories: motor problems and co-
ordination, visual complaints, headache, cosmetic
and dermatological complaints, gastrointestinalcomplaints, and sexuality and menses were com-
bined as physical complaints. The categories gen-
eral CNS, behavior, depressive symptoms, and
cognitive function reflected mental complaints.
All statistical analyses were performed with SPSS
version 12.0, Chicago, IL, USA.Results
Between October 2002 and July 2005, 173 patients
were included in the study. Patient characteristics
are shown in Table 1. The distribution of subjective
complaints as measured by the SIDAED ranged from
0 to 84 (possible range 0—138), with a median of 10.
Only nine patients (5%) mentioned no complaints at
all (Fig. 1).
The complaints score for each of the 10 categories
is shown in Fig. 2. Cognitive dysfunction was men-
tioned by 78% of patients, 35% reported only mild
complaints, 28% (mild and) moderate complaints,
and 15% (also) reported severe cognitive complaints.
Other categories of complaints that were mentioned
by more than half of the patients concerned general
CNS, gastrointestinal problems, dermatological or
cosmetic problems, and depressive symptoms.
The total weighted complaints score was associ-
atedwiththequalityof life,withpsychoneuroticism,
with polytherapy, with the time since last seizure,
and with the number of used AEDs over the years
(Table 2). The linear regression coefficients indicate
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Figure 1 Distribution of total weighted subjective com-
plaints score (SIDAED).
Figure 2 Subjective complaints per category.Patients
were counted in the level of highest reported severity,
e.g. a patient with moderate and severe problems within
one category, was counted as severe.the change in number of total weighted complaints
score with every unit increase of the determinant.
Thus, more complaints occurred when more AEDs
were used over the years, with use of polytherapy
compared to monotherapy, and with higher psycho
neuroticism score (SCL-90). Less subjective com-
plaints occurred with increasing time since the last
seizure and a low total complaints score was asso-
ciated with a high quality of life score (Qolie-10).
In the multivariable linear regression analysis, we
included the determinants with a high univariableTable 2 Univariable association between total weighted




Sex (female versus male) 3.24
Body mass index, BMI (kg/m2) 0.40
Localization related epilepsy (yes vs. no) 1.71
Generalized epilepsy (yes versus no) 0.36
Duration of epilepsy (years) 0.06
Number of seizures during the last month 0.02
Time since last seizure (years) 0.41
Number of used AEDs over the years 1.54
Polytherapy AED (yes versus no) 7.50
Qolie-10 score 9.70
SCL-90 score 0.32
95% CI = 95% confidence interval of linear regression coefficient.
Table 3 Multivariable association between total weighted
Adjusted R 2 Linea
Model 0.61
Sex (female/male) 2.06
Time since last seizure (years) 0.07




95% CI = 95% confidence interval of linear regression coefficient.association (p-value<0.05) with the total weighted
complaints score as outcome (Table 3). Our choice of
possible determinants of subjective complaints
seemed appropriate as the total model showed an
adjusted R2 of 61%, leaving only 39% unexplained
variance. The SCL-90 score contributed most to the




0.08 to 0.17 0.49
0.93 to 7.42 0.13
0.91 to 0.11 0.13
2.57 to 5.99 0.43
4.46 to 5.19 0.88
0.14 to 0.25 0.58
0.10 to 0.14 0.71
0.76 to 0.06 0.02
0.02 to 3.07 0.05
1.73 to 13.27 0.01
12.00 to 7.40 <0.01
0.29 to 0.36 <0.01
subjective complaint score and included determinants
r regression coefficient 95% CI P-value
0.79 to 4.90 0.16
0.40 to 0.07 0.16
0.64 to 1.72 0.37
0.61 to 8.30 0.09
2.70 to 2.11 0.82
0.25 to 0.35 <0.01
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Figure 3 Reported subjective complaints (SIDAED) and
physical and mental effects of AEDs (Qolie-10).For the
SIDAED, patients were counted in the level of highest
reported severity, e.g. a patient with moderate and
severe problems on the physical or mental categories
was counted as severe.be overlooked in the multivariable model, which
may be due to partial overlap of the Qolie-10 and
the SCL-90. When the SCL-90 score was excluded
from the multivariable analysis, the adjusted R2
decreased to 30% and polytherapy still contributed
to the complaints score (p-value 0.05) as well as the
Qolie-10 score with a linear regression coefficient
of 8.62 (95% confidence interval 11.13 to 6.11)
and a p-value <0.01.
Assessing subjective complaints with the SIDAED
and reporting physical and mental effects of AEDs
on the Qolie-10 differed substantially (Fig. 3). In
total, 95% of patients mentioned complaints on the
SIDAED, of whom 116 (67%) at least one moderate
or severe complaint. On the other hand, on the
Qolie-10 only 33% of the patients mentioned physi-
cal side-effects from AEDs (18% moderate to severe)
and only 23% mentioned mental side-effects from
AEDs (11% moderate to severe).Discussion
Our study shows that 67% of patients who were
considered well-controlled reported subjective
complaints. Cognitive complaints were most fre-
quently mentioned. The two most important factors
related to reported complaints were medication
use, i.e. whether the patient used mono- or poly-
therapy, and personality traits, i.e. higher scores
on psycho neuroticism.
The patient characteristics of our population are
in agreement with what we expected of patients
with well-controlled epilepsy, continuing on the
same AED for years: 28% of our study population
was over 60 years of age, patients were diagnosedwith epilepsy a long time ago and most patients
received monotherapy.
The percentage of patients with moderate to
severe subjective complaints concur with the study
by Carpay et al. (67% versus 60%).2 However, Carpay
et al. focused on all patients using AEDs in a certain
community, regardless of whether the seizures were
under control or not, while we assessed seemingly
well-controlled patients, using AEDs for many
years.11 Gilliam et al. assessed the prevalence of
toxic side-effects of AEDs in patients, selected from
an outpatient epilepsy clinic with severe epilepsies,
probably with a worse seizure control compared to
our study population.5 These studies already indi-
cated that systematic screening for side-effects of
AEDs or complaints associated with AED use prob-
ably will improve the well being of patients, as was
also suggested in an editorial based on the paper by
Gilliam et al.6 Our results show that in seemingly
well-controlled patients, reported subjective com-
plaints are unexpectedly high and that systematic
screening can be useful to detect these complaints.
In clinical practice, the physician will ask the
patient whether there are any problems regarding
the medication. Since our patient population is con-
sidered well-controlled, we may conclude that most
patients will answer with no. Asking a more specific
question, like in the Qolie-10: ‘‘Are you bothered by
physical/mental effects of anti-epileptic drugs?’’,
detects moderate to severe problems in one-third
of these patients. Checkingwhether patients subjec-
tively experience side-effects through a thorough list
of specific complaints, covering a number of domains
(as in the SIDAED), revealed complaints in two-third
of the patients. This may indicate that patients often
do not associate experienced complaints with their
chronic AED use, resulting in an under detection of
AED side-effects related complaints in every day
clinical practice,which again stretches that systema-
tic screening can be useful.
Most of the variation in subjective complaints, as
measured by the SIDAED,was explained by the deter-
minants included in our models, especially polyther-
apy and psycho neuroticism.We expect that the type
of AED may be part of the 39% unexplained variance
of complaints. In a subsequent trial we will assess
whether changing the medication in patients report-
ing subjective complaints has a positive effect on the
reported complaints and on quality of life.
Cognitive complaints and general CNS reactions
were mentioned frequently. Also when we take the
number of items per category into account, com-
plaints were most frequently mentioned in these
two categories. This is in agreement with earlier
studies.2,7,12 Although the epilepsy itself may
cause memory deficit and therefore cognitive
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1 I have problems with my gums
2 I have lost weight
3 I have difficulty remembering names
4 I often feel drowsy and sleepy
5 I sometimes have to hold on to something to
stop myself from falling
6 I forget all sorts of things, such as appointments
7 I find it hard to concentrate
8 I tire easily and have little energy
9 I am easily aggressive
10 I can only concentrate on something for
short periods
11 I constantly walk into tables, doorposts etc.
12 I feel agitated and restless
13 I notice my reaction to others is slow
14 I cannot concentrate on the same thing for
long periods of time
15 I notice my speech is slow
16 I constantly feel pressurized and excitable
17 I often suffer from dizzy spells
18 I have little appetite
19 My periods are irregular
20 I notice I sometimes have difficulty expressing
myself
21 I often feel nauseous
22 I worry all day
23 I often suffer from diarrhea
24 My hands shake all the time
25 I have surplus saliva
26 I often suffer from double vision
27 I suffer from skin rash or other skin problems
28 I have gained weight
29 I think more slowly than I used to
30 I am easily irritated
31 I feel depressed and miserable
32 My bowel movement is often difficult
33 I have difficulty finding the right words
34 I am becoming less and less activecomplaints,13,14 studies have shown that memory
impairment is multifactorial and that AEDs can
reduce memory performance.14 Furthermore,
the age of the participants did not play a role in
reported cognitive complaints, since there was no
association found between age and reported com-
plaints, even when we only analyzed cognitive
complaints ( p-value 0.24).
We are aware that the SIDAED complaints ques-
tionnaire measures subjective complaints, which is
not the same as a neuropsychological assessment
method. However, our purpose was to assess the
daily routine in normal clinical practice, where
neuropsychological assessments are usually not per-
formed in well-controlled patients. For the treating
physician, it will be more informative to know
whether the patient suffers from certain subjective
complaints than to have exact neuropsychological
information, especially when changing medication
might remedy these subjective complaints.
We chose not to include a control group to assess
subjective complaints in people that do not use
AEDs. Possibly, subjective complaints from the
SIDAED list will be reported in other populations,
even in healthy ones. However, for our purpose,
which was to assess subjective complaints in well-
controlled patients with epilepsy using AEDs, this
was less relevant. Furthermore, the distribution of
mentioned complaints concurs to what we expected
in our research population.2,7,12
The weights to assess the severity of the men-
tioned complaints were arbitrarily applied. How-
ever, changing the applied weights to 1, 3 and 5
instead of 1, 2 and 3 for mild, moderate and severe,
respectively, yielded the same results: SCL-90 and
polytherapy still had the strongest association with
the total weighted subjective complaints score.
The SCL-90, measuring psycho neuroticism, con-
tributed most to the model explaining the presence
of complaints, which reflects the general associa-
tion between emotional lability and a tendency to
complain. However, the ‘‘patient with well-con-
trolled epilepsy’’ is not more neurotic than the
standard population, since the SCL-90 score of our
population did not differ from the norm population.9
The Qolie-10 (quality of life) and the SCL-90
(psycho neuroticism) probably are partly overlap-
ping measures. This may explain the non-significant
contribution of the Qolie-10 in the multivariable
model that also included the SCL-90. After exclusion
of the SCL-90, the Qolie-10 contributes significantly
to the model ( p-value <0.01), confirming a partial
overlap between the two measures.
In conclusion, our results indicate that in clinical
practice complaints among patients with epilepsy
whoareconsideredwell-controlledby theirphysicianare very common. Both treatment characteristics
and aspects of personality contribute to the presence
and severity of complaints. The question whether
patients experience side-effects from their medi-
cation is not thesameasasking specifically for certain
complaints and systematic screening to detect sub-
jective complaints can be useful in daily clinical
practice.
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Appendix A. SIDAED list of subjective
complaints
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35 I cannot get to sleep and often lie awake
36 I am less often in the mood for sex
37 Sometimes I cannot do anything because
of headaches
38 I suffer from hair loss
39 My vision is blurred
40 My hair growth has increased
41 When I want to pick up something, my hands
start shaking
42 I do not feel capable of performing normal
my daily activities
43 I often suffer from headaches
44 Making love has become less pleasant
45 I often suffer from stomach trouble
46 I often feel light-headed
Severity was stated as no problem/mild/moderate/serious pro-
blem. Duration was stated as since a few weeks/months/half a
year or longer.
Appendix A (Continued )Appendix B. SIDAED questionnaire
items per categoryCategory Included itemsGeneral CNS 4, 8, 14, 42
Behavior (increased irritability) 9, 12, 16, 30
Depressive symptoms 22, 31, 34, 35
Cognitive function 3, 6, 7, 10, 13,
15, 20, 29, 33
Motor problems and
co-ordination5, 11, 17, 24,
41, 46Visual complaints 26, 39
Headache 37, 43
Cosmetic and dermatological
complaints1, 25, 27, 38,
40, 45Gastrointestinal complaints 2, 18, 21, 23,
28, 32Sexuality and menses 19, 36, 44References
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